2013
DOI: 10.1086/669706
|View full text |Cite
|
Sign up to set email alerts
|

Intellectual Property Rights and Innovation: Evidence from the Human Genome

Abstract: Do intellectual property (IP) rights on existing technologies hinder subsequent innovation? Using newlycollected data on the sequencing of the human genome by the public Human Genome Project and the private firm Celera, this paper estimates the impact of Celera's gene-level IP on subsequent scientific research and product development. Genes initially sequenced by Celera were held with IP for up to two years, but moved into the public domain once re-sequenced by the public effort. Across a range of empirical sp… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

8
159
0
1

Year Published

2014
2014
2020
2020

Publication Types

Select...
8
2

Relationship

0
10

Authors

Journals

citations
Cited by 314 publications
(179 citation statements)
references
References 40 publications
8
159
0
1
Order By: Relevance
“…However, from our point of view, recombination and incremental improvements are critical to innovation and patents can also stifle these processes by inhibiting the flow of information across individual minds, instead incentivizing secrecy. Consistent with this, historical analyses of patent laws by Moser [97] and recent analyses of human gene patents by Williams [98] both suggest that patent laws may often be too strong, reducing innovation, but this does not mean no patents would lead to more innovation. Based on data on pharmaceutical patents in 92 countries from 1978 to 1992, Qian [99] argues that there may be an optimal level of protection, after which innovation is stifled.…”
Section: (A) Increasing Innovation Ratesmentioning
confidence: 94%
“…However, from our point of view, recombination and incremental improvements are critical to innovation and patents can also stifle these processes by inhibiting the flow of information across individual minds, instead incentivizing secrecy. Consistent with this, historical analyses of patent laws by Moser [97] and recent analyses of human gene patents by Williams [98] both suggest that patent laws may often be too strong, reducing innovation, but this does not mean no patents would lead to more innovation. Based on data on pharmaceutical patents in 92 countries from 1978 to 1992, Qian [99] argues that there may be an optimal level of protection, after which innovation is stifled.…”
Section: (A) Increasing Innovation Ratesmentioning
confidence: 94%
“…Our research also relates to (and was inspired) the observation that research, innovation, and technical advance tend to advance in an incremental fashion within defined paradigms, knowledge trajectories, research pathways, or dominant designs-some basic approach to solving the problem-that is then incrementally refined through a continuous series of cumulative, incremental advances (e.g., Kuhn 1962, Dosi 1982, Sahal 1985, Romer 1990, Gibbons et al 1994, Murray and O'Mahony 2007, Furman and Stern 2011, Williams 2013, Boudreau and Lakhani 2015. This overriding tendency toward within-paradigm, incremental advance rather than more novel and exploratory innovations might be explained by any number of mechanisms, such as the strategic incentives and organization of innovators (e.g., Kuhn 1962, Utterback and Abernathy 1975, March 1991, Manso 2011.…”
Section: Contributions and Relationships To Literaturementioning
confidence: 99%
“…There is an extensive literature that examines the impact of regulatory institutions on innovation. Institutions may affect a country's innovation capacity (Furman, Porter, & Stern, 2002), utilize existing research and increase cumulative knowledge (Furman & Stern, 2011; Williams, 2013), affect license timing and facilitate technological trade (Gans, Hsu, & Stern, 2008), flow of knowledge transfer (Murray & Stern, 2007) and follow‐on innovation (Sampat & Williams, 2019). In this article, we focus on the role of institutions in how organizations utilize an existing innovation across different markets.…”
Section: Theoretical Backgroundmentioning
confidence: 99%